Healthcare Industry News: Pegasus
News Release - April 10, 2006
Pegasus' HeartVue 6S System Successfully Demonstrated to Cardiologists at ACC 55th Scientific Session Exposition in AtlantaPALM BEACH GARDENS, FL--(Healthcare Sales & Marketing Network)--Apr 10, 2006 -- Pegasus/HeartView, LLC (Other OTC:PGUZ.PK ) today reports on the excellent results from the showing of its superior, non-invasive heart screening technology, the HeartVue 6S System, at the American College of Cardiology Scientific Session in Atlanta, Georgia early last month.
Pegasus showcased its fast, non-invasive heart screening technology which provided 3 dimensional images of the heart onsite to many of the more than 15,000 cardiologists who attended the show, an event for medical professionals from around the globe. The HeartVue 6S System provided superior cardiac imaging from an electrocardiogram (ECG) signal to create a 3 dimensional image of the heart onsite to hundreds of interested attendees. The technology uses new information from ECG fluctuations that are usually ignored as "noise" by regular electrocardiogram devices. The technology portrays an image of the heart's electrical field dynamics, allowing for rapid recognition and estimation of the heart's condition. The Company received inquiries for distribution rights from the U.S., Europe, Japan, India and Australia. Several leading cardiologists agreed to co-operate in continuing a series of clinical trials for the HeartVue 6S System, which will be headed up by Dr. Vladimir Grishin, the President of HeartView, LLC.
Pegasus Pharmaceuticals holds a majority interest in HeartView, LLC, which in turn holds the worldwide patent, manufacturing and marketing rights of the HeartVue 6S System. An earlier version of this screening system has already been cleared for sale in Europe and there is a patent pending in the United States.
For corporate information, please contact Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals and HeartView, LLC at: (561) 626-9901. Email: email@example.com. For investor information, contact Paul Davey at (778) 389-0915. Visit the Pegasus' website at: www.Pegasusbiosciences.com
Source: Pegasus Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.